Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 28, 2014BloodOpen Access

Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura

View Full Paper
Ask AI
Bookmark
Share

Authors

JGJulie GayLGLionel GalicierFPFrançois Provôt

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Gay et al. (2014) studied this question.

synapsesocial.com/papers/6a96e2bf0f79e4f014b3113ehttps://doi.org/10.1182/blood-2014-01-550244
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Rituximab maintenance for relapsed refractory thrombotic thrombocytopenic purpura2012 · 20 citations
  2. 2Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases2005 · 279 citations
  3. 3Thrombotic Microangiopathies: Towards a Pathophysiology-Based Classification2009 · 74 citations
  4. 4Prognostic value of anti-ADAMTS13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS13 activity2006 · 295 citations
  5. 5Relapses of thrombotic thrombocytopenic purpura after treatment with rituximab2013 · 18 citations